BVSBioventus Inc.
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (A) and big price swings.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -95% · now 17% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BVS take a bad year?
Bioventus Inc. carries $219M of net debt at 2.62× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · between two and four years of EBITDA, normal for a stable business
- Net debt / EBITDA
- 2.62×
Net debt / EBITDA · 4.94× a year ago · the load is coming down
- Debt / equity
- 1.09×
Debt / equity
- Annualised volatility
- 55%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $248M
- Cash and short-term investments
- $29M
- Net debt
- $219M
- EBITDA, trailing twelve months
- $84M
- Operating profit, trailing twelve months
- $58M
- Debt / equity
- 1.09×
- Total debt / EBITDA
- 2.97×
- Annualised volatilitytwo years of daily moves
- 55%
- Worst drawdown on file
- −95%
- Below its 52-week high
- 17%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Medical Devices
Ranks #18 of 51 by RyuScore